Oxford BioTherapeutics

Precision cancer immunotherapy through target discovery

Oxford, CA, UK

Oxford BioTherapeutics (OBT) is a clinical-stage oncology company based in Oxford, UK, and San Jose, USA. It is dedicated to discovering and developing first-in-class antibody-based therapies for cancer, with a pipeline including immuno-oncology and antibody-drug conjugate therapies.

Shareable draft

Check out Oxford BioTherapeutics on @MedStartr Today Oxford BioTherapeutics (OBT) is a clinical-stage oncology company based in Oxford, UK, and San Jose, USA. It is dedicated to discovering and developing first-in-class antibody-based therapies for cancer, with a pipeline including immuno-oncology and antibody-drug conjugate therapies. #SolidTumors #AcuteMyeloidLeukemia #MentalBehavioralHealth #HematologicMalignancies #NonSmallCellLungCancer #CancerOncology #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/j6o01Ks_3BM

Get Involved in Oxford BioTherapeutics

How We Help

Problem Statement

Developing first-in-class antibody-based therapies to address unmet needs in cancer treatment.

Core Technology

Proprietary proteomic target discovery platform called OGAP®-Verify, based on one of the world's largest proprietary cancer membrane proteomic databases.

Key Differentiators

First-in-class antibody-based therapies for cancer; Proprietary proteomic target discovery platform (OGAP®-Verify)

Clinical Focus

Immuno-oncology; Antibody-drug conjugates

Company Info

Business Model: B2B
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.oxfordbiotherapeutics.com/

Disease Areas

Solid Tumors Acute Myeloid Leukemia Mental Health Hematologic Malignancies Non-Small Cell Lung Cancer Cancer & Oncology

Technologies

Antibody-Based TherapiesAntibody-Drug ConjugateBispecificCAR-TADCC TherapeuticsProteomicsTarget DiscoveryOncologyImmuno-OncologyADCBispecific AntibodiesAntibody Therapeutics

Clinical & IP

🔬

Clinical Validation

Phase 1b active for OBT076 (CD205 ADC); FDA IND cleared; initial Phase 1 data: 7/18 patients clinical benefit, optimal dose 3.0 mg/kg, well tolerated; Phase 2a planned for NSCLC, ovarian, gastric cancers; Phase 1b with checkpoint inhibitor combinations shows near-complete responses.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Oxford BioTherapeutics?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.